Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly. Approximately 50% of AMD patients have a polymorphism in the negative regulator of complement known as Factor H. Individuals homozygous for a Y402H polymorphism in Factor H have elevated levels of membrane attack complex (MAC) in their choroid and retinal pigment epithelium relative to individuals homozygous for the wild-type allele. An inability to form MAC due to a polymorphism in C9 is protective against the formation of choroidal neovascularization (CNV) in AMD patients. Hence, blocking MAC in AMD patients may be protective against CNV. Here we investigate the potential of human proline/arginine-rich end leucine-rich repeat protein (PRELP) as an inhibitor of complement-mediated damage when delivered via the subretinal route using an AAV2/8 vector. In a fluorescenceactivated cell sorting (FACS) lysis assay, PRELP inhibited normal human serum-mediated lysis of Hepa-1c1c7 cells by 18.7%. Unexpectedly, PRELP enhanced the formation of tubes by human umbilical vein endothelial cells (HUVECs) by approximately 240%, but, when delivered via an AAV vector to the retina of mice, PRELP inhibited laser-induced CNV by 60%. PRELP reduced deposition of MAC in vivo by 25.5%. Our results have implications for the development of complement inhibitors as a therapy for AMD.
INTRODUCTION
Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly, affecting approximately one in three people over the age of 70. 1 Approximately 90% of AMD patients suffer from the 'dry' or non-exudative form of AMD. The remaining patients suffer from 'wet' or exudative AMD, involving the growth of new blood vessels from the choroid into the subretinal space, that is, choroidal neovascularization (CNV). 2 Whereas 'wet' AMD may be treated with anti vascular endothelial growth factor (VEGF) molecules, there are currently no treatment options for 'dry' AMD. In general, 'dry' AMD progresses to 'wet' AMD in 10% of patients, but both forms of the disease can also exist concomitantly. Although the cause of AMD is not well understood, significant evidence has accumulated that complement has a key role in the disease process. 3 For example, 50% of AMD patients have a polymorphism in the complement regulator Factor H with a common Y402H variant present in approximately 43% of AMD patients. 4 Activation of complement terminates in the formation of a pore known as the membrane attack complex (MAC) on the surface of pathogens and host tissues. 5 Low levels of MAC on host tissues lead to an elevation of cytokines such as VEGF, 6 whereas high levels of MAC lead to cell lysis. 7 Damage to host tissues is prevented by the expression of regulators of complement such as CD59 and CD46. 8 Advanced AMD patients have reduced levels of CD59 and CD46 on their RPE cells, 9 and loss of RPE cells is a hallmark of advanced AMD known as geographic atrophy. 3 Individuals homozygous for the Y402H polymorphism in Factor H have approximately 70% more MAC on their choroidal blood vessels, RPE and the associated Bruch's membrane. 3 An inability to form MAC by virtue of a polymorphism in C9, an essential protein for the formation of MAC, protects individuals from the development of 'wet' AMD. 10 Notably, Factor H with a Y402H polymorphism binds less efficiently to heparan sulfate and dermatan sulfate glycosaminoglycans within Bruch's membrane than wild-type (WT) Factor H. 11 On the basis of the above collective observations, a model is emerging that suggests an imbalance between complement activation and complement inhibition may have a significant role in the pathogenesis of AMD. We postulate that inhibition of local complement activation and particularly inhibition of MAC deposition on host tissues may protect against the conversion of 'dry' to 'wet' AMD.
PRELP (proline/arginine-rich end leucine-rich repeat protein) is an aproximately 42 to 58 kDa extracellular matrix protein [12] [13] [14] [15] [16] found in connective tissues such as the sclera, tendon, skin, lung and heart. 13, 15 The N terminus of PRELP has been shown to bind both heparin and heparan sulfate proteoglycans in the extracellular matrix. 17 PRELP also binds perlecan, a component of the Bruch's membrane. 18 PRELP is a recently identified inhibitor of C9 polymerization, 14 a process necessary for assembly of the MAC.
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PRELP also interacts with C3 and different polymorphisms in C3 have been shown to promote or reduce the risk of AMD. 20, 21 To date, the anticomplement activities of PRELP have not been investigated in vivo.
The most commonly used model of 'wet' AMD is laser-induced CNV. 22, 23 In this model, a laser is utilized to disrupt the Bruch's membrane, which leads to an elevation of cytokines such as VEGF and subsequent development of CNV. This model has been widely used to measure the efficacy of inhibitors of angiogenesis and particularly CNV. [22] [23] [24] In addition to the process of CNV, in this model there is deposition of MAC at the site of the laser burn. 25 Hence, while this model has some limitations as a true model for 'wet' AMD, it is an ideal model to test the efficacy of inhibitors of CNV and MAC. In this study, we test the hypothesis that expression of human PRELP in the murine retina via an adeno-associated virus (AAV) vector attenuates the progression of laser-induced CNV and deposition of the MAC. Our results have potential implications for the future development of anticomplement therapies for AMD.
RESULTS

PRELP inhibits normal human serum-mediated cell lysis
In order to determine whether PRELP may protect cells from complement-mediated cell lysis, we constructed a plasmid containing an expression cassette expressing the human PRELP cDNA regulated by the CMV enhancer/chicken β-actin promoter and a rabbit globin poly adenylation (pA) signal. As we wished to ultimately express PRELP in vivo, we flanked the PRELP expression cassette with adeno-associated virus serotype 2 (AAV2)-inverted terminal repeats (pAAV2-PRELP, Figure 1a ). As a negative control, we constructed a similar plasmid devoid of the PRELP cDNA (pAAV2-pA, Figure 1a ). Western blot analyses of media from human ARPE-19 cells transfected with pAAV2-PRELP indicated an immunostained protein band of approximately 44 kDa, consistent with the predicted molecular weight of 43.84 kDa (http://www. bioinformatics.org/sms2/protein_mw.html) of human PRELP ( Figure 1b ). As expected, this band was absent in samples containing media from ARPE-19 cells transfected with pAAV2-pA ( Figure 1b) . In a standard fluorescence-activated cell sorting (FACS) lysis assay, a total of 90.16 ± 1.09% of murine Hepa-1c1c7 cells incubated in 1.5% normal human serum (NHS) were lysed by NHS preconditioned with media from human ARPE-19 cells transfected with pAAV2-pA (Figures 1c and d) . In contrast, a total of 71.42 ± 3.79% of Hepa-1c1c7 cells incubated in 1.5% NHS were lysed when the NHS was preconditioned with media from human ARPE-19 cells transfected with pAAV2-PRELP (Figures 1c and d) , corresponding to an approximately 18.74 ± 3.95% (P = 0.0015) reduction in NHSmediated cell lysis. In conclusion, we show that PRELP significantly inhibits NHS-mediated cell lysis of Hepa-1c1c7 cells.
Human PRELP promotes formation of tubes by HUVECs Endothelial cell migration and subsequent formation of tubes is a generally accepted prerequisite of angiogenesis. New blood vessels formed in 'wet' AMD leak blood and plasma to form a macular edema. VEGF is a vascular permeability factor, and the occurrence of macular edema is associated with elevated VEGF. One commonly used standard assay to measure the potency of inhibitors of tube formation involves the counting of master junctions, master segments or meshes formed by human umbilical vein endothelial cells (HUVECs) in the presence or absence of a reagent predicted to attenuate tube formation. Hence, we incubated HUVEC cells with a commercially available mix of growth factors that activate and promote the formation of tubes by HUVECs and supplemented this mix with either media from pAAV2-PRELP-transfected ARPE-19 cells or media from pAAV2-pAtransfected ARPE-19 cells. As a negative control, we included suramin, an inhibitor of HUVEC tube formation. Suramin completely blocked the formation of junctions, segments or meshes in these assays (data not shown). We found that HUVECs cultured in pA-preconditioned medium formed an average of 8.52 ± (Figures 2a and b) . Contrary to our expectations, our data indicated that there was a 2.1-fold increase in the formation of master junctions (P o 0.0001), a 2.3-fold increase in the formation of master segments (P o 0.0001) and a 2.9-fold increase in formation of meshes (P o0.0001), respectively, when HUVECs are incubated in pAAV2-PRELP-preconditioned media relative to pAAV2-pA-preconditioned media. We conclude that expression of human PRELP enhanced the formation of tubes by HUVECs. Nonetheless, as HUVECs are not a surrogate for in vivo studies and choroidal endothelial cells in culture would not necessarily predict the outcomes of endothelial cells in vivo, we proceeded to evaluate the activity of human PRELP in vivo.
Expression of human PRELP in the murine retina AAV vectors are efficient gene delivery vehicles for the murine and human retina. 26 In order to deliver the PRELP cDNA to the murine retina, we utilized an AAV2/8-PRELP vector and an AAV2/8-pA vector as the corresponding negative control. To determine the localization of human PRELP following delivery to the murine retina, AAV2/8-PRELP or AAV2/8-pA was injected into the subretinal space of adult C57Bl/6J mice. Two weeks later, the mice were killed and frozen retinal sections examined for expression of human PRELP by immunocytochemistry. As PRELP is a secreted protein found in the extracellular matrix, we wished to distinguish PRELP localization independently of gene expression associated with the tropism of AAV2/8, that is, we wished to distinguish regions of the retina that contained PRELP that had not been directly infected by the virus vector. Hence, before subretinal injection, the AAV2/8-PRELP or AAV2/8-pA virus preparations were 'spiked' with AAV2/8-GFP. We found that GFP in AAV2/8-PRELP injected eyes was present in the outer nuclear layer (ONL) and the retinal pigment epithelium (RPE) (Figure 3a ). In these same sections, PRELP was found abundantly in the inner retina and outer segments, but, unexpectedly, not in the ONL (Figure 3b ). AAV2/8-pA-injected mice stained for human PRELP were negative as expected ( Figure 3c ) as were uninjected mice (Figure 3i ). At higher magnification, we found that GFP was also present abundantly in the outer segments ( Figure 3d ) and that staining within the ONL was perinuclear (Figures 3d, f and g ). An overlay of the GFP and Cy3 signal associated with PRELP staining (yellow) indicated areas of overlap but also areas of clear distinction between GFP expression and localization of PRELP (Figure 3f ). These data suggest that following subretinal injection, PRELP is synthesized in the photoreceptors and RPE and thereafter secreted. PRELP subsequently localizes to the inner retina as well as the outer retina except in the ONL. In contrast, GFP is present only in the photoreceptors and RPE, consistent with the presumed transduction pattern of AAV2/8-GFP.
Human PRELP attenuates CNV in mice In order to determine whether human PRELP can attenuate laserinduced CNV, AAV2/8-PRELP or AAV2/8-pA was injected into the subretinal space of 6-week-old C57Bl/6J mice, and, 2 weeks later, four laser spots were created in the choroid equidistant from the optic nerve head. Further 7 days thereafter, mice were killed and eyes were collected, stained with GSL-1 lectin (Figure 4a ) and the area of CNV quantified using Image J Software (http://rsbweb.nih. gov/ij/). The average area of CNV spot size in AAV2/8-pA-injected eyes was found to be 3.025 ± 0.355 × 10 4 μm 2 (n = 61 laser spots, 10 mice/20 eyes). In contrast, the average area of CNV spot size in AAV2/8-PRELP-injected eyes was 1.250 ± 0.138 × 10 4 μm 2 (n = 55 laser spots, 10 mice/20 eyes), corresponding to a 60.0 ± 13.1% (P o 0.0001) reduction in laser-induced CNV (Figure 4b ). We conclude that human PRELP attenuates laser-induced CNV in C57Bl/6J mice.
Human PRELP attenuates formation of MAC in mice Formation of the MAC begins with the incorporation of the C5b678 complex into the surface of cell membranes followed by the recruitment and polymerization of multiple C9 units to form C5b9. 27 In order to determine whether a reduction in CNV was associated with a reduction in MAC, we stained AAV2/8-PRELPinjected eyes or AAV2/8-pA-injected eyes with an antibody against C5b9. We found that, for similar-sized laser spots, C5b9 staining extended beyond the region of the GSL-1-stained CNV in AAV2/8-pA-injected eyes (Figure 5a ). In contrast, in AAV2/8-PRELP-injected eyes, C5b9 staining did not extend beyond the GSL-1-stained CNV, and staining was overall weaker within the CNV. Quantification of the signal intensity/area revealed an average ratio of 3.376 ± 0.288 × 10 4 U μm −2 in AAV2/8-pA-injected eyes (n = 61 laser spots, 10 mice/20 eyes) and of 2.516 ± 0.300 × 10 4 U μm
in AAV2/8-PRELP-injected eyes (n = 55 laser spots, 10 mice/20 eyes), corresponding to a significant reduction in MAC staining of approximately of 25.5 ± 12.3% (P = 0.0409; Figure 5b ). We conclude that human PRELP attenuates murine MAC deposition in laserinduced CNV.
DISCUSSION
In this study, we report that human PRELP promotes the formation of tubes by HUVEC cells in vitro, yet inhibits angiogenesis and specifically CNV in vivo. We also report that human PRELP significantly inhibits NHS-mediated lysis in vitro and inhibits formation of murine MAC in vivo. These results confirm a role for complement activation in laser-induced CNV and demonstrate for the first time in vivo, the anticomplement activities of human PRELP. These studies shed further light on the functions of PRELP and have potential implications for the development of anticomplement therapies for AMD. Although AMD is a complex disorder, significant evidence indicates that activation of complement has a significant role in disease pathology. Balance between activation and inhibition of complement is maintained by a number of proteins. Polymorphisms in complement Factors/proteins H, C3, C2, C1, B, I, D and C4 have been previously associated with AMD.
3,28,29 Polymorphisms 1-fold (***P o0.0001), master segments by 2.3-fold (***P o0.0001) and meshes by 2.9-fold for (***P o0.0001). Studies were performed four times in triplicate (n = 12).
in Factor H can be found in approximately 50% of AMD patients, and homozygosity for a frequent Y402H polymorphism leads to an almost 70% increase in MAC deposition in the choroidal blood vessels, RPE and Bruch's membrane-the primary sites of pathology in AMD patients. 3, 4, 28 An inability to form MAC due to a polymorphism in C9 protects against wet AMD in humans. 10 Complement is also involved in tissue homeostasis, and particularly in angiogenesis, apoptosis, cytokine release and chemotaxis of macrophages 30 -all factors previously implicated in AMD. 31, 32 Hence, complement may have a role in the pathogenesis of AMD not only through MAC but also through its interactions with other key biological pathways. On the basis of these and additional criteria, we were motivated to identify and test molecules that may inhibit complement activation and specifically CNV and MAC deposition in murine models of AMD. In general, proteins that are found to be efficacious as inhibitors of angiogenesis or specifically CNV in vivo also tend to function as inhibitors of endothelial tube formation in vitro. Hence, HUVECs in culture are often utilized as a surrogate for angiogenesis in vivo. Despite this, we were surprised to find that instead of inhibiting the formation of tubes by HUVECs, PRELP enhanced tube formation more than twofold. This observation could be explained by considering that the complement cascade has a significant role in angiogenesis in vivo, 33 but, in the HUVEC tube formation assay in vitro, the complement cascade is largely absent and hence angiogenesis in the in vitro model is primarily driven by factors other than complement, such as cytokines. This hypothesis is also consistent with the knowledge that the extracellular matrix also has a key role in angiognenesis in vivo, 34 and cells in culture have a limited extracellular matrix relative to that in vivo. The N terminus of PRELP has been previously described to bind and localize to the extracellular matrix. 17 In our own studies, the immunostaining pattern for PRELP appeared to be extracellular (Figures 3e and f) relative to the expression of GFP that was primarily perinuclear in the ONL (Figures 3d, f and g ) and nuclear and cytoplasmic in the RPE (Figures 3d, f and h) .
The complement system can be activated through three different pathways, the classical, the lectin and the alternative pathway. These pathways converge into the terminal pathway that results in the deposition of MAC. PRELP interferes with the formation of MAC by inhibiting polymerization of C9, an essential component of MAC. 14, 19 PRELP also inhibits the alternative pathway of complement by inhibiting the formation of the C3-convertase C3bBbP. 14 Hence, PRELP may be acting at various stages of complement activation in order to reduce laser-induced CNV and MAC deposition. Previously, we have described an AAV2 vector expressing human CD59 with a deletion in the GPI anchor of CD59 (AAVCAGsCD59). Similar to PRELP, CD59 blocks the completion of the formation of MAC. 30 However, CD59 is not known to attenuate complement at additional stages of complement activation. Expression of CD59 on the RPE of advanced AMD patients is diminished relative to normal individuals, and this may potentially expose the RPE cells to MAC-associated lysis or cause an elevation in cytokine release through the deposition of MAC. Although attenuation of complement at various stages of activation through the use of PRELP has its advantages in terms of potentially greater potency, it may also be disadvantageous given that complement has various roles in tissue homeostasis. 35 In our studies involving AAVCAGsCD59, we found a 62% reduction in CNV 25 and 73% reduction in MAC, respectively (our unpublished results). In the current study utilizing PRELP, we observed a comparable 60% reduction in CNV but a 25% reduction in MAC. However, these two studies cannot be directly compared because we utilized different serotypes of AAV vectors between the different studies as well as different modes of vector delivery to the eye. However, both studies corroborate that inhibition of complement and inhibition of MAC attenuate CNV. Thus far, these are the only studies utilizing a gene therapy approach for the inhibition of complement in animal models of AMD. Given that the AAV2 vector has been shown to be safe and persists long-term in humans, 36 and, that AMD is a slow chronic disease, it is tempting to believe that a gene therapy approach to deliver inhibitors of complement to human eyes may be efficacious for the treatment of AMD. Overlays of GSL-1 and C5b9 stainings of equal-sized CNV spots, indicating MAC deposition confined within borders of CNV in AAV2/8-PRELP-infected eyes, but spread beyond the CNV area in the negative controls. Note that there was variability in GSL-1 staining between laser spots, and this was overcome by use of a relatively large sample size. In the above figure, two spots of roughly equivalent GSL-1 staining were selected in order to demonstrate the corresponding differences in C5b9 staining. (b) Graphical plot of mean values ± s.e.m. of C5b9 intesity/area ratios in AAV2/8-pA-and AAV2/8-PRELP-injected eyes. Average ratio was significantly reduced by 25.5 ± 12.3% (*P = 0.0409) in AAV2/8-PRELP-infected eyes. Studies were performed twice with five mice in each group (n = 10 mice/20 eyes; AAV2/8-pA: 61 laser spots, AAV2/8-PRELP: 55 laser spots).
MATERIALS AND METHODS
supplemented with 10% FBS. Human retinal pigment epithelium cells (ARPE-19; CRL-2302; ATCC, Manassas, VA, USA) were maintained in phenol red-free DMEM/F-12 (Life Technologies) supplemented with 10% FBS. All cell lines were propagated at 37°C in a humidified 5% CO 2 -air incubator.
Generation of AAV constructs
The coding sequence of human PRELP was amplified by PCR from IMAGEclone 5222817 (MGC-45323; ATCC) using primers hPrelp fwd. (5′-GAATTCA TGAGGTCACCCCTCTGCTG-3′) and hPrelp rev. (5′-CTCGAGCTAGATGACCA CGGACTGCAG-3′). The PCR product was cloned in a pAAV2 vector containing a CMV enhancer /chicken β-actin promoter (CAG) to generate pAAV2-Prelp. The sequence of the cloned PCR product was verified by Tufts University Sequencing Core. AAV2/8 production and purification were performed as described previously. 25 In brief, AAV-293 cells were triple transfected using CaPO 4 with pAAV2-Prelp, pHelper and replication/ serotype 8 capsid-plasmid pRC/8 (Agilent Technologies, Santa Clara, CA, USA). PEG-precipitated medium/cell lysate mixtures were purified by highspeed IDX-density-gradient centrifugation and concentrated with sepharose spin columns. Purity of viruses was assessed in silver-stained polyacrylamide gels indicating major proteins corresponding to AAV8 VP1 (87 kDa), VP2 (72 kDa) and VP3 (62 kDa) as expected (Supplementary Figure 1) . Virus titers were determined by AAV2-specific real-time PCR quantification of virus genomes as described previously.
37 AAV2/8-pA control virus was generated in a similar manner. NHS-mediated cell lysis assay FACS lysis assays were performed as previously described. 25 In brief, 5.0 × 10 4 Hepa-1c1c7 cells per assay were resuspended in either PRELP-or pA-conditioned medium. NHS was added to 1.5%. Cells were allowed to react for 1 h at 37°C with constant gentle rotary motion. Cell lysis was measured as uptake of propidium iodide in 2. 
HUVEC tube formation assay
Tube formation assays were carried out according to the Endothelial Tube Formation Assay (in vitro angiogenesis) protocol (Life Technologies).
In brief, 4.5 × 10 4 HUVECs per assay were seeded in either PRELP-or pA-conditioned medium on Geltrex (reduced growth factor basement membrane matrix; Life Technologies)-coated wells of a 24-well plate. Tube formation was induced with 2% low serum growth supplement (LSGS). Cells were analyzed after 16-20 h under an inverted microscope (IX51; Olympus, Center Valley, PA, USA) and images captured. Numbers of master junctions, master segments and meshes in each image were quantified using the 'HUVEC angiogenesis analyzer' plugin for the ImageJ software.
Animals
This study was carried out in strict accordance with the Statement for the Use of Animals in Ophthalmic and Vision Research, set out by the Association of Research in Vision and Ophthalmology (ARVO) and was approved by Tufts University Institutional Animal Care and Use Committee (IACUC) protocol B2011-150 and Tufts University Institutional Biosafety Committee registration 2011-BRIA68. For experiments, 6-week-old C57Bl/6J mice (Jackson laboratory, Bar Harbor, ME, USA) were used. Animals were anesthetized by intraperitoneal injections of a mixture containing 0.1 mg g − 1 body weight Ketamine (Phoenix, St Joseph, MO, USA) and of 0.01 mg g − 1 body weight Xylazine (Lloyed, Shenandoah, IA, USA). Mice were kept warm during anesthesia. Mice were killed by CO 2 inhalation followed by cervical dislocation.
Subretinal injections
Subretinal injections were performed as previously described. 25 In brief, 2.8 × 10
10 genome copies of AAV2/8-PRELP were delivered in a total volume of 1 μl by a trans-scleral/ trans-choroidal approach with a 32 G needle attached to a 5 -μl glass syringe (Hamilton, Reno, NV, USA). PRELP virus was injected in both eyes of mice (n = 10 mice, 20 eyes). The corresponding control cohort was injected with AAV2/8-pA following the same protocol.
Posterior eyecup labeling
Localization of PRELP in the posterior eye was determined 2 weeks after injection. Mice were killed, eyes enucleated, opened by a transcorneal punch and fixed by immersion in 4% PFA in toto. Eyes were dehydrated in 15 and 30% sucrose, cornea and lens removed and specimens embedded in Tissue-Tek Cryo-O.C.T. Compound (Electron Microscopy Sciences, Hatfield, PA, USA). Twelve-micrometre thick sections were made on a cryostat (Microm HM550) and dried onto microscope slides. Sections were blocked in PBS/6% NGS/0.1% TritonX-100, labeled with a rabbitpolyclonal-anti-hPRELP antibody (1:250 in blocking solution; SAB1100370, Sigma-Aldrich) and detected with a Cy3-conjugated goat-anti-rabbit antibody (1:400 in PBST; Jackson ImmunoResearch Laboratories). Nuclei were counterstained with DAPI.
For detection of CNV area and MAC, mice were killed 7 days after lasering and the eyes enucleated. Cornea, iris, lens and the neuronal retina were removed and posterior eye segments fixed by immersion in 4% PFA. RPE/choroid specimens were cut four times from the edge to the center to obtain trefoil-shaped flatmounts. After blocking in PBS/2.5 mg ml − 1 BSA, flatmounts were stained with FITC-conjugated Griffonia Simplicifolia Lectin I (GSL I, isolectin B4; 10 mg ml À 1 in PBS; Vector Labs, Burlingame, CA, USA). Specimens were washed with PBS, reblocked with 6% normal goat serum (NGS; Jackson ImmunoResearch Laboratories, West Grove, PA, USA) in PBS/ 0.3% TritonX-100 (PBST) and labeled with a rabbit-anti-hC5b9 antibody (1:200 in PBST; Complement Technology, Tyler, TX, USA). Detection was done with a Cy3-conjugated goat-anti-rabbit antibody (1:400 in PBST; Jackson ImmunoResearch Laboratories). Flatmounts were analyzed under an inverted microscope (IX51; Olympus) attached to a fluorescence unit and images captured. Areas of GSL-I labeling (CNV areas), size and signal intensities of C5b9-labeled areas (MAC areas) were measured using ImageJ software. Data points for MAC deposition are depicted as C5b9 intensities per C5b9 area ratios. C5b9 intensities were corrected for background intensities before calculations. Area and intensity measurements were analyzed with GraphPad Prism6 (GraphPad Software, La Jolla, CA, USA) using an unpaired student's t-test. All data is presented as mean ± s.e.m.
Laser-induced CNV
Laser-induced CNV was performed as described previously. 25 In brief, pupils of anesthetized mice were dilated with one drop each of 2.5% phenylephrine HCl and 1% Tropicamide (Bausch & Lomb Incorporate, Tampa, FL, USA). The cornea was protected with one drop of 2.5%
